Exploring BCL-XL addiction in pancreatic ductal adenocarcinoma

 描述(申请人提供)：胰腺导管腺癌(PDAC)是一种致命的疾病，治愈率低，治疗方案少。我们最近发现，在我们实验室测试的胰腺癌细胞株中，大约50%(31株中的14株)对选择性bcl-xl抑制剂WEHI-539高度敏感。因此，我们将评估bclxl在体外和体内作为PDAC治疗靶点的潜在疗效。此外，我们还将确定bclxl成瘾的潜在生物标志物，表征其敏感性和耐药性的机制，并发现新的药物组合以进一步增强bclxl抑制剂在PDAC中的活性。

 DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a low cure rate and few therapeutic options. We recently discovered that approximately 50% of the pancreatic cancer cell lines tested in our lab (14 out of 31 lines) are highly sensitive to the selective BCL-XL inhibitor WEHI-539. Therefore, we will evaluate the potential efficacy of BCL-XL as a therapeutic target in PDAC both in vitro and in vivo. In addition, we will identify potential biomarkers of BCL-XL addiction, characterize mechanisms of sensitivity and resistance, and uncover novel drug combinations to further potentiate the activity of BCL-XL inhibitors in PDAC.